Overexpression of MET protein has been reported in 25 to 75% of cases, depending on the antibody and cutoff value used in the implemented immunohistochemistry (IHC) assays as well as the histological NSCLC subtypes analyzed [2,3,4,5]. This evidence concerns the gene MET and non-small cell lung carcinoma.